Not recruiting

Study on the Effects of Metoprolol Tartrate for Patients with Chronic Obstructive Pulmonary Disease (COPD) Without Cardiovascular Disease

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Seloken, which contains the active ingredient metoprolol tartrate. The study is specifically looking at patients with Chronic Obstructive Pulmonary Disease (COPD), a lung condition that makes it hard to breathe. The purpose of the study is to see if using this medication can help protect against worsening of COPD, heart-related events, and death in patients who have COPD but no other heart diseases.

Participants in the study will be given either Seloken or a placebo. The medication is taken orally in the form of a tablet. The study will last for up to 12 months, during which time the health of the participants will be monitored to see if there are any changes in their condition. The researchers will be looking at how long it takes for any serious health events to occur, such as worsening of COPD symptoms, heart attacks, or strokes.

The study aims to gather information on whether Seloken can be beneficial for people with COPD in terms of reducing the risk of serious health issues. This information could help in understanding the potential benefits of using beta-blockers, like metoprolol tartrate, in managing COPD. The results will also include an analysis of the economic impact of using this treatment.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, the patient must have a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) through a breathing test called spirometry. This test measures the amount of air the patient can exhale in one second and compares it to the total amount of air exhaled.
The patient must be at least 40 years old and have a history of smoking or exposure to smoke, gas, or dust. The heart rate should be between 50 and 120 beats per minute at the time of joining.
Written informed consent is required to participate in the study.
Step 2
Medication administration
The patient will receive a medication called Seloken, which contains the active ingredient metoprolol tartrate. This medication is a type of beta-blocker.
Seloken is available in two dosages: 50 mg and 100 mg tablets. The medication is taken orally.
The specific dosage and frequency of administration will be determined by the study protocol and the patient's individual needs.
Step 3
Monitoring and follow-up
Throughout the study, the patient will be monitored for any changes in their health, particularly focusing on the occurrence of COPD exacerbations, cardiovascular events, and overall survival.
The study aims to determine if beta-blocker treatment can protect against these health issues in patients with COPD who do not have existing heart disease.
Step 4
Study duration
The study is expected to continue until December 31, 2025.
During this time, data will be collected and analyzed to assess the effectiveness and safety of the treatment.

Who can join the trial?

5 criteria

Have a confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD). This is a lung condition that makes it hard to breathe. The diagnosis should be confirmed by a test called spirometry, which measures how well your lungs work. The test should show a specific result called FEV1/FVC less than 70, according to guidelines.
Have a history of smoking or exposure to smoke, gas, or dust at work or in the environment.
Be 40 years of age or older.
Have a heart rhythm called sinus rhythm with a heart rate of 50 to less than 120 beats per minute at the time of joining the study.
Be able to provide written informed consent, which means you understand the study and agree to participate.

Who cannot join the trial?

3 criteria

Patients with **Chronic Obstructive Pulmonary Disease (COPD)** who also have other heart-related diseases cannot participate. **COPD** is a lung condition that makes it hard to breathe.
Patients who are not within the specified age range for the study cannot participate. The study is looking for people in certain age groups.
Patients who are part of a vulnerable population, meaning they might need special protection or care, are not eligible for this study.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Karolinska University Hospital
Verified
Solna, Sweden
Region Oestergoetland
Responsive
Linkoping, Sweden
Region Vaesterbotten
Responsive
Umea, Sweden

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Beta-blockers are medications commonly used to manage heart conditions by slowing down the heart rate and reducing blood pressure. In this trial, they are being studied to see if they can help patients with Chronic Obstructive Pulmonary Disease (COPD) who do not have any existing heart disease. The goal is to find out if beta-blockers can reduce the number of COPD flare-ups, prevent heart-related problems, and lower the risk of death in these patients.

Metoprolol Tartrate

What is already known about the treatment

Beta-blockers – These medications are typically administered orally in tablet form. They are currently being studied for their potential benefits in patients with chronic obstructive pulmonary disease (COPD) without co-existing cardiovascular disease. The main therapeutic indication being explored is the prevention of COPD exacerbations, cardiovascular events, and death. At the molecular level, beta-blockers work by blocking the effects of adrenaline on beta receptors, which helps to reduce heart rate and blood pressure. They are classified as beta-adrenergic blocking agents in pharmacology.

Investigated diseases

Chronic Obstructive Pulmonary Disease – This is a long-term lung condition that makes it hard to breathe. It is characterized by a persistent blockage of airflow from the lungs, leading to breathing difficulties. The disease progresses slowly and is often caused by long-term exposure to irritating gases or particulate matter, most commonly from cigarette smoke. Over time, symptoms such as chronic cough, mucus production, and shortness of breath become more severe. As the disease advances, it can lead to frequent respiratory infections and increased difficulty in performing daily activities. The condition is not reversible, but its progression can be managed with lifestyle changes and medical interventions.